IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

VERDE, FEDERICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.073
AS - Asia 7.060
NA - Nord America 6.804
SA - Sud America 745
Continente sconosciuto - Info sul continente non disponibili 662
AF - Africa 150
OC - Oceania 58
Totale 22.552
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.400
IT - Italia 2.743
CN - Cina 2.059
SG - Singapore 1.926
DE - Germania 1.890
BD - Bangladesh 1.051
HK - Hong Kong 625
BR - Brasile 586
GB - Regno Unito 516
VN - Vietnam 429
RU - Federazione Russa 426
NL - Olanda 311
FR - Francia 301
IN - India 296
CA - Canada 274
SE - Svezia 162
IE - Irlanda 161
KR - Corea 139
ID - Indonesia 121
FI - Finlandia 119
JP - Giappone 85
TR - Turchia 80
ES - Italia 73
AR - Argentina 55
AU - Australia 54
DK - Danimarca 54
CI - Costa d'Avorio 52
UA - Ucraina 42
IQ - Iraq 40
PL - Polonia 39
AT - Austria 36
CH - Svizzera 35
CO - Colombia 29
MX - Messico 29
PH - Filippine 27
BE - Belgio 25
CL - Cile 24
CZ - Repubblica Ceca 21
CR - Costa Rica 20
PK - Pakistan 20
ZA - Sudafrica 20
JM - Giamaica 19
TW - Taiwan 19
EG - Egitto 18
SA - Arabia Saudita 18
EC - Ecuador 17
GR - Grecia 16
IR - Iran 15
KE - Kenya 15
UZ - Uzbekistan 15
LU - Lussemburgo 13
VE - Venezuela 13
PT - Portogallo 12
RO - Romania 12
LT - Lituania 11
GT - Guatemala 10
MY - Malesia 10
NO - Norvegia 10
JO - Giordania 9
MA - Marocco 9
NP - Nepal 9
PY - Paraguay 9
TH - Thailandia 9
TT - Trinidad e Tobago 9
HN - Honduras 8
HU - Ungheria 8
NI - Nicaragua 8
UY - Uruguay 7
DZ - Algeria 6
IL - Israele 6
MD - Moldavia 6
SC - Seychelles 6
AE - Emirati Arabi Uniti 5
BB - Barbados 5
CY - Cipro 5
LI - Liechtenstein 5
PR - Porto Rico 5
SV - El Salvador 5
TN - Tunisia 5
AM - Armenia 4
EE - Estonia 4
ET - Etiopia 4
HR - Croazia 4
KZ - Kazakistan 4
MM - Myanmar 4
NZ - Nuova Zelanda 4
PS - Palestinian Territory 4
AL - Albania 3
AZ - Azerbaigian 3
BH - Bahrain 3
BO - Bolivia 3
BY - Bielorussia 3
BZ - Belize 3
GA - Gabon 3
OM - Oman 3
PA - Panama 3
BA - Bosnia-Erzegovina 2
BF - Burkina Faso 2
BG - Bulgaria 2
GE - Georgia 2
Totale 21.849
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 1.600
Singapore 1.021
Ashburn 877
Milan 598
Hong Kong 521
San Jose 482
Hefei 403
Santa Clara 387
Council Bluffs 349
Dallas 349
Southend 332
Beijing 254
Los Angeles 242
New York 209
Rome 187
Chandler 156
Bengaluru 153
Dublin 152
Ho Chi Minh City 137
Buffalo 125
Lauterbourg 118
Boardman 117
Hanoi 116
Seattle 116
Jakarta 98
Toronto 97
Seoul 88
Fairfield 84
Naples 84
Moscow 80
Turin 78
Guangzhou 77
The Dalles 73
Chicago 67
Helsinki 65
Wilmington 63
Shanghai 62
Princeton 61
São Paulo 58
Virginia Beach 58
Munich 57
Houston 53
Istanbul 53
Abidjan 52
Bologna 46
Nuremberg 45
Ann Arbor 44
London 44
Montreal 44
Tokyo 39
Florence 37
Orem 37
Ponte San Pietro 37
Lappeenranta 36
Atlanta 35
Phoenix 34
Des Moines 33
Lake Charles 33
Milwaukee 33
Nanjing 33
Da Nang 32
Dearborn 32
Piscataway 29
Secaucus 29
Lexington 28
Cambridge 27
North Bergen 27
Washington 27
Bari 26
San Francisco 26
Woodbridge 26
Las Vegas 25
Palermo 25
Tianjin 25
Genoa 24
Skokie 24
Warsaw 24
Changsha 23
Newark 23
Brooklyn 22
Cangzhou 22
Fuzhou 22
Rio de Janeiro 22
Wuhan 22
Hangzhou 21
Utebo 21
Amsterdam 20
Brussels 20
Clifton 20
Twentynine Palms 20
Monza 19
Brescia 18
Columbus 18
Lowell 18
San José 18
Silver Spring 18
Sydney 18
Yongin-si 18
Bergamo 17
Berlin 17
Totale 11.932
Salva come PNG Salva come JPEG
Nome #
Further insights into anti-IgLON5 disease: a case with complex clinical presentation 562
Regional spreading pattern is associated with clinical phenotype in amyotrophic lateral sclerosis 423
Standardization of the Italian ALS-CBS™ Caregiver Behavioral Questionnaire 413
Diagnostics and clinical usability of the Montreal Cognitive Assessment (MoCA) in amyotrophic lateral sclerosis 379
Diagnostic properties of the Italian ECAS Carer Interview (ECAS-CI) 350
Genome-wide Analyses Identify KIF5A as a Novel ALS Gene 348
Clinical usability of the Story-Based Empathy Task (SET) in non-demented ALS patients 338
Cerebrospinal fluid phosphorylated neurofilament heavy chain and chitotriosidase in primary lateral sclerosis 328
ALS-associated missense and nonsense TBK1 mutations can both cause loss of kinase function 326
Analysis of hnRNPA1, A2/B1, and A3 genes in patients with amyotrophic lateral sclerosis 323
The validation of the Italian Edinburgh cognitive and behavioural ALS screen (ECAS) 312
NEK1 variants confer susceptibility to amyotrophic lateral sclerosis 306
Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis 303
Validity and diagnostics of the Reading the Mind in the Eyes Test (RMET) in non-demented amyotrophic lateral sclerosis (ALS) patients 294
The Frontal Assessment Battery (FAB) effectively discriminates between MCI and dementia within the clinical spectrum of neurochemically confirmed Alzheimer’s disease 292
Oligoclonal bands in the cerebrospinal fluid of amyotrophic lateral sclerosis patients with disease-associated mutations 292
Association of the risk factor UNC13A with survival and upper motor neuron involvement in amyotrophic lateral sclerosis 290
Bridging the Gap of ALS Missing Heritability: Are Neurogenes Being Overlooked? 265
Motor, cognitive and behavioural profiles of C9orf72 expansion-related amyotrophic lateral sclerosis 265
Shaping the Neurovascular Unit Exploiting Human Brain Organoids 260
The impact of upper motor neuron involvement on clinical features, disease progression and prognosis in amyotrophic lateral sclerosis 255
Unleashing the potential of mRNA therapeutics for inherited neurological diseases 248
Mechanism-free repurposing of drugs for C9orf72-related ALS/FTD using large-scale genomic data 238
Diagnostic properties of the Frontal Assessment Battery (FAB) in Huntington’s disease 229
Bulbar involvement and cognitive features in amyotrophic lateral sclerosis: a retrospective study on 347 patients 229
Clinimetrics and feasibility of the Italian version of the Frontal Assessment Battery (FAB) in non-demented Parkinson’s disease patients 224
Verbal learning in frontal patients: area 9 is critical for employing semantic strategies 221
Frontotemporal-spectrum disorders and functional independence in non-demented ALS patients 214
Lower semantic fluency scores and a phonemic-over-semantic advantage predict abnormal CSF P-tau181 levels in Aβ + patients within the Alzheimer's disease clinical spectrum 213
Validity, diagnostics and feasibility of the Italian version of the Montreal Cognitive Assessment (MoCA) in Huntington's disease 212
A novel nonsense ATP7A pathogenic variant in a family exhibiting a variable occipital horn syndrome phenotype 212
TMEM106B Acts as a Modifier of Cognitive and Motor Functions in Amyotrophic Lateral Sclerosis 210
CSF Aβ40 and P-tau181 might differentiate atypical from typical AD phenotypes : preliminary evidence 202
TARDBP mutations in a cohort of Italian patients with Parkinson’s disease and atypical parkinsonisms 202
Correlation between clinical phenotype and electromyographic parameters in amyotrophic lateral sclerosis 200
Human salivary Raman fingerprint as biomarker for the diagnosis of Amyotrophic Lateral Sclerosis 197
Phosphorylated tau in plasma could be a biomarker of lower motor neuron impairment in amyotrophic lateral sclerosis 196
Neurofilament Light Chain as Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia 195
Identification of Novel Biomarkers of Spinal Muscular Atrophy and Therapeutic Response by Proteomic and Metabolomic Profiling of Human Biological Fluid Samples 194
Phenotypic correlates of serum neurofilament light chain levels in amyotrophic lateral sclerosis 194
Modeling Electric Fields in Transcutaneous Spinal Direct Current Stimulation: A Clinical Perspective 194
Gaze-Contingent Eye-Tracking Training in Brain Disorders: A Systematic Review 191
The value of routine blood work-up in clinical stratification and prognosis of patients with amyotrophic lateral sclerosis 191
Reliable change indices for the Italian version of the Montreal Cognitive Assessment (MoCA) in non-demented Parkinson’s disease patients 188
Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis : a multicenter study 188
Ecological Validity of the Montreal Cognitive Assessment in Non-Demented Parkinson's Disease Patients 187
CSF angiogenin levels in amyotrophic lateral Sclerosis-Frontotemporal dementia spectrum 187
Exploring epigenetic drift and rare epivariations in amyotrophic lateral sclerosis by epigenome-wide association study 186
Exploiting the role of CSF NfL, CHIT1, and miR-181b as potential diagnostic and prognostic biomarkers for ALS 181
Mutations in the vesicular trafficking protein Annexin A11 are associated with amyotrophic lateral sclerosis 177
Characterization of human healthy i3 lower motor neurons exposed to CSF from ALS patients stratified by UNC13A and C9ORF72 genotype 173
Emotional processing and experience in amyotrophic lateral sclerosis: A systematic and critical review 173
Genomic and transcriptomic advances in amyotrophic lateral sclerosis 172
Serum levels of glial fibrillary acidic protein in patients with amyotrophic lateral sclerosis 171
Association of clinically evident eye movement abnormalities with motor and cognitive features in patients with motor neuron disorders 171
PON1 is a disease modifier gene in amyotrophic lateral sclerosis : association of the Q192R polymorphism with bulbar onset and reduced survival 167
Digital health and Clinical Patient Management System (CPMS) platform utility for data sharing of neuromuscular patients: the Italian EURO-NMD experience 166
Influence of kidney function and CSF/serum albumin ratio on plasma Aβ42 and Aβ40 levels measured on a fully automated platform in patients with Alzheimer’s disease 165
KIF5Ap.Pro986Leu Risk Variant and Accelerated Progression of Amyotrophic Lateral Sclerosis 163
Advancing Italian biomedical information extraction with transformers-based models: Methodological insights and multicenter practical application 162
Feasibility and diagnostics of the Frontal Assessment Battery (FAB) in amyotrophic lateral sclerosis 162
Primary progressive aphasia and motor neuron disease: A review 158
Plasma levels of glial fibrillary acidic protein and neurofilament light chain in patients with chronic migraine: a multicenter case-control study 156
Clinical usefulness of the Verbal Fluency Index (VFI) in amyotrophic lateral sclerosis 155
The role of de novo mutations in the development of amyotrophic lateral sclerosis 155
Duropathy as a rare motor neuron disease mimic: from bibrachial amyotrophy to infratentorial superficial siderosis 154
Investigating the prevalence of MFN2 mutations in amyotrophic lateral sclerosis: insights from an Italian cohort 154
An exploratory study on counterfactual thinking in amyotrophic lateral sclerosis 154
MRI abnormalities found 1 year prior to symptom onset in a case of Creutzfeldt–Jakob disease 154
Prevalence and determinants of language impairment in non-demented amyotrophic lateral sclerosis patients 152
Incidence and Long-term Functional Outcome of Neurologic Disorders in Hospitalized Patients With COVID-19 Infected With Pre-Omicron Variants 151
Quantification of serum TDP-43 and neurofilament light chain in patients with amyotrophic lateral sclerosis stratified by UNC13A genotype 150
Italian reference values and brain correlates of verbal fluency index - vs standard verbal fluency test - to assess executive dysfunction in ALS 150
Serum neurofilament light chain levels in Covid-19 patients without major neurological manifestations 146
An old woman with pressure ulcer, rigidity, and opisthotonus: never forget tetanus! 143
Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS 139
Semiology and determinants of apathy across neurodegenerative motor disorders: A comparison between amyotrophic lateral sclerosis, Parkinson's and Huntington's disease 137
Coexistence of Amyotrophic Lateral Sclerosis and Alzheimer’s Disease: Case Report and Review of the Literature 135
Single task-level, 2SD-based cutoffs for the Italian version of the Edinburgh Cognitive and Behavioral ALS screen (ECAS) 134
Validity and diagnostics of the Italian version of the Montreal Cognitive Assessment (MoCA) in non-demented Parkinson's disease patients 133
Cerebrospinal fluid/serum albumin quotient (Q-Alb) is not increased in Alzheimer's disease compared to neurological disease controls: a retrospective study on 276 patients 128
Equating norms between the ALS Cognitive Behavioral Screen (ALS-CBS™) and the Edinburgh Cognitive and Behavioural ALS Screen (ECAS) in non-demented ALS patients 127
Characterization of human healthy i3 lower motor neurons exposed to CSF from ALS patients stratified by UNC13A and C9ORF72 genotype 127
Relationship between cerebrospinal fluid/serum albumin quotient and phenotype in amyotrophic lateral sclerosis: a retrospective study on 328 patients 126
Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview 126
Upper motor neuron dysfunction is associated with the presence of behavioural impairment in patients with amyotrophic lateral sclerosis 123
Phosphorylated tau 181 and 217 are elevated in serum and muscle of patients with amyotrophic lateral sclerosis 120
Behavioral disorders of spatial cognition in patients with mild cognitive impairment due to Alzheimer’s disease (The BDSC-MCI Project): ecological validity of the Corsi learning suvra-span test 118
Association of APOE genotype and cerebrospinal fluid Aβ and tau biomarkers with cognitive and motor phenotype in amyotrophic lateral sclerosis 118
Clinimetrics of the cognitive section of the Italian ALS Cognitive Behavioral Screen (ALS-CBS™) 114
Amyotrophic Lateral Sclerosis: Neurochemical Biomarkers 113
Correction to: Verbal learning in frontal patients: area 9 is critical for employing semantic strategies 112
Identification of the Raman Salivary Fingerprint of Parkinson’s Disease Through the Spectroscopic– Computational Combinatory Approach 111
Next-generation sequencing application to investigate skeletal muscle channelopathies in a large cohort of Italian patients 110
Association of Vascular Risk Factors and Cerebrovascular Pathology With Alzheimer Disease Pathologic Changes in Individuals Without Dementia 108
Neural Surface Antibodies and Neurodegeneration: Clinical Commonalities and Pathophysiological Relationships 105
Screening properties of the updated normative framework for the Italian MMSE in MCI and dementia 104
Progressive motor neuron syndromes with single CNS lesions and CSF oligoclonal bands : never forget solitary sclerosis! 104
Association between renin-angiotensin-aldosterone system inhibitors and risk of dementia : a meta-analysis 103
A + T ± status across MCI and dementia due to AD: a clinic-based, retrospective study 103
Totale 19.779
Salva come PNG Salva come JPEG
Categoria #
all - tutte 63.738
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 63.738
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022510 0 0 37 39 51 23 42 27 99 66 25 101
2022/2023966 64 56 74 51 78 157 49 73 135 49 90 90
2023/20242.575 93 106 77 182 366 168 279 227 136 253 333 355
2024/20254.203 323 415 289 358 194 189 278 355 255 391 386 770
2025/202611.010 896 929 960 739 579 502 1.289 465 1.158 844 1.383 1.266
2026/20271.889 1.135 749 5 0 0 0 0 0 0 0 0 0
Totale 22.552